MedTrace Logo

Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

NCT03542877 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-07-15

Study results available
· View outcomes & findings →

Summary

This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.

Conditions

Interventions

DRUG

Oral Tablet: Cabozantinib

Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • Academic Thoracic Oncology Medical Investigators Consortium

    lead INDUSTRY

Principal Investigators

  • Wells Messersmith, MD · University of Colorado, Denver

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2020-10-19
Completion
2022-03-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542877 on ClinicalTrials.gov